Below you will find example sentences with "gilead sciences". The examples show how this phrase is used in natural context and which words often surround it.
Gilead Sciences in a sentence
Corpus data
- Displayed example sentences: 20
- Discovered as a combination around: sciences
- Corpus frequency in the collocation scan: 17
- Phrase length: 2 words
- Average sentence length: 20.8 words
Sentence profile
- Phrase position: 8 start, 12 middle, 0 end
- Sentence types: 20 statements, 0 questions, 0 exclamations
Corpus analysis
- The phrase "gilead sciences" has 2 words and usually appears in the middle in these examples. The average sentence has 20.8 words and is mostly made up of statements.
- Around this phrase, patterns and context words such as holdings in gilead sciences were worth, agreement with gilead sciences inc on, quarter, 000 and shares stand out.
- In the phrase index, this combination connects with life sciences, health sciences, social sciences, life sciences, health sciences and social sciences, linking the page to nearby combinations.
Example types with gilead sciences
This selection groups the examples by length and sentence type, making usage of the full phrase easier to scan:
Gilead Sciences’s revenue was up 5.4% compared to the same quarter last year. (15 words)
Morgan Stanley grew its stake in Gilead Sciences by 11.5% during the 4th quarter. (15 words)
Finally, started coverage on shares of Gilead Sciences in a research note on Thursday, March 16th. (16 words)
Beacon Investment Advisory Services Inc. cut its holdings in Gilead Sciences, Inc. () by 0.5% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. (30 words)
Jubilant Life Sciences has entered into a non-exclusive licensing agreement with Gilead Sciences, Inc on the prospective Covid-19 drug Remdesivir, for India and other select countries. (28 words)
Novartis, Gilead Sciences, Spark Therapeutics, Amgen, Orchard Therapeutics, Bristol-Myers Squibb, BioMarin, PTC Therapeutics, and Organogenesis are the leading players in the cell and gene therapy market. (27 words)
Example sentences (20)
Given Gilead Sciences’ higher probable upside, analysts clearly believe Gilead Sciences is more favorable than Enzon Pharmaceuticals.
In other Gilead Sciences news, insider sold 2,000 shares of Gilead Sciences stock in a transaction dated Wednesday, February 28th.
Jubilant Life Sciences has entered into a non-exclusive licensing agreement with Gilead Sciences, Inc on the prospective Covid-19 drug Remdesivir, for India and other select countries.
According to data from MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $86.
Archford Capital Strategies LLC’s holdings in Gilead Sciences were worth $683,000 at the end of the most recent quarter.
Bank Julius Baer & Co. Ltd Zurich’s holdings in Gilead Sciences were worth $31,530,000 as of its most recent SEC filing.
Beacon Investment Advisory Services Inc. cut its holdings in Gilead Sciences, Inc. () by 0.5% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission.
Concord Wealth Partners acquired a new stake in Gilead Sciences during the 4th quarter worth approximately $33,000.
Concord Wealth Partners acquired a new stake in Gilead Sciences in the fourth quarter worth $33,000.
Finally, Ergoteles LLC bought a new position in shares of Gilead Sciences during the 1st quarter worth approximately $2,304,000.
Finally, JFS Wealth Advisors LLC raised its holdings in shares of Gilead Sciences by 68.1% during the third quarter.
Finally, started coverage on shares of Gilead Sciences in a research note on Thursday, March 16th.
Gilead Sciences’s revenue was up 5.4% compared to the same quarter last year.
In my opinion, Gilead Sciences should be able to grow at least in the mid-single digits in the years to come.
In other Gilead Sciences news, CFO sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 17th.
Morgan Stanley grew its stake in Gilead Sciences by 11.5% during the 4th quarter.
Novartis, Gilead Sciences, Spark Therapeutics, Amgen, Orchard Therapeutics, Bristol-Myers Squibb, BioMarin, PTC Therapeutics, and Organogenesis are the leading players in the cell and gene therapy market.
On average, analysts predict that Gilead Sciences, Inc. will post 6.83 earnings per share for the current year.
Finally, Brandywine Global Investment Management LLC boosted its holdings in Gilead Sciences by 33.9% in the third quarter.
Finally, upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Tuesday, March 26th.